Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase—Effect of cMOAT Deficiency on Hepatobiliary Excretion in Rats and of mdr 1a/b Gene Disruption on Tissue Distribution in Mice

Aoki, 1997, Pharmacological profile of novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzme A reductase, Arzneim Forsch/Drug Res, 47, 904 Suzuki, 1999, Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs, Atherosclerosis, 146, 259, 10.1016/S0021-9150(99)00146-X Kajinami, 2000, NK-104, a novel synthetic HMG-CoA reductase inhibitor, Exp Opin Invest Drugs, 9, 2653, 10.1517/13543784.9.11.2653 Kimata, 1998, Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats, Xenobio Metabol Dispos, 13, 484 Ishikawa, 2000, New nomenclature of human ABC transporter genes, Xenobio Metabol Dispos, 15, 8 Kusuhara, 1998, The role of P-glycoprotein and canalicular multispecific oraganic anion transporter in the hepatobiliary excretion of drugs, JPharm Sci, 87, 1025, 10.1021/js970100b Kurisu, 1991, Organic anion transport study in mutant rats with autosomal recessive conjugated hyperbilirubinuria, Life Science, 49, 1003, 10.1016/0024-3205(91)90301-Q Sathirakul, 1994, Multiple transport systems for oraganic anions across the bile canalicular membrane, J Pharmacol Exp Ther, 268, 65 Schinkel, 1997, Normal viability and altered pharmacokinetics in mice laking mdr1-type (drug-transporting) P-glycoproteins, Proc Natl Acad Sci, 94, 4028, 10.1073/pnas.94.8.4028 Asperen, 2000, The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice, Drug Metab Dispos, 28, 264 Kojima, 1999, Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile, Biol Pharm Bull, 22, 142, 10.1248/bpb.22.142 Sarkadi, 1992, Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase, J Biol Chem, 267, 4854, 10.1016/S0021-9258(18)42909-2 Scarborough, 1995, Drug-stimulated ATPase activity of the human P-glycoprotein, J Bioenerg Biomembr, 27, 37, 10.1007/BF02110329 Ambudkar, 1999, Biochemical, cellular, and pharmacological aspects of the multidrug transporter, Annu Rev Pharmacol Toxicol, 39, 361, 10.1146/annurev.pharmtox.39.1.361 Fujino, 1999, Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): Interspecies variation in laboratory animals and humans, Xenobio Metabol Dispos, 14, 79 Kojima, 2001, Effect of biliary excretion on the pharmacokinetics of pitavastatin (NK-104) in dogs, Xenobio Metabol Dispos, 16, 497 Yamazaki, 1996, Primary active transport of pravastatin across the liver canalicur rats, Biopharm Drug Dispos, 17, 645, 10.1002/(SICI)1099-081X(199611)17:8<645::AID-BDD986>3.0.CO;2-L Yamazaki, 1997, Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT), Drug Metab Dispos, 25, 1123 Takikawa, 1995, Mechanism of biliary excretion of lithocholate-3-sulfate in Esai hyperbilirubinemic rats (EHBR), Dig Dis Sci, 40, 1792, 10.1007/BF02212704 Ohmori, 1991, Decrease in the specific forms of cytochrome P450 in liver microsomes of a mutant strain of rat with hyperbilirubinuria, Res Commun Chem Pathol Pharmacol, 72, 243 Fujino, 1999, Studies on the metabolic fate of NK-104, a new inhibitor HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human, Xenobio Metabol Dispos, 14, 415 Smit, 1999, Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure, J Clin Invest, 104, 1441, 10.1172/JCI7963 Fujino, 1998, Studies on the metabolic fate of NK-104, a new inhibitor HMG-CoA reductase (3): Foeto-placental transfer and mammary excretion after oral administration in rats, Xenobio Metabol Dispos, 13, 508 Sakaeda, 2002, Simvastatin and lovastatin, but not pravastatin, interact with MDR1, J Pharm Pharmacol, 54, 419, 10.1211/0022357021778493 Boyd, 2000, Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein mediated secretion, J Clin Pharmacol, 40, 91, 10.1177/00912700022008612 Bogman, 2001, HMG-CoA reductase inhibitors and P-glycoprotein modulation, Br J Pharmacol, 132, 1183, 10.1038/sj.bjp.0703920 Kusus, 2000, Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions, Am J Med Sci, 320, 394, 10.1097/00000441-200012000-00007